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Abstract
Background: Sentinel lymph node biopsy (SLNB) is well accepted to be a standard procedure in breast cancer
surgery with clinically negative lymph nodes. Isosulfan blue is the first dye approved by the USA Food and Drug
Administration for the localization of the lymphatic system. Few alternative tracers have been investigated. In this
study, we aimed to compare the differences between 10 % fluorescein sodium and 1 % isosulfan blue in breast
sentinel lymph node biopsy and to investigate the feasibility of using 10 % fluorescein sodium as a new dye for
breast sentinel lymph node biopsy.
Methods: A total of 30 New Zealand rabbits were randomly divided into the fluorescein sodium group and the
isosulfan blue group (15 rabbits per group). Fluorescein sodium or isosulfan blue was injected subcutaneously into
the second pair of mammary areolas.
Results: The average fading time of the second lymph nodes in the isosulfan blue group was significantly shorter
than that in the fluorescein sodium group. Moreover, the detection rates of SLNs were higher in the fluorescein
sodium group than in the isosulfan blue group. No significant differences between the fluorescein sodium group
and isosulfan blue group were observed regarding the distances between the detected sentinel lymph nodes and
second pair of mammary areolas, the distances between the second lymph nodes and second pair of mammary
areolas, the number of detected sentinel lymph nodes and second lymph nodes, the average dyeing time of the
sentinel and the second lymph nodes, and the average fading time of the second lymph nodes.
Conclusions: In summary, we first reported that fluorescein sodium is a potential new tracer for breast sentinel
lymph node biopsy.
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Background
Breast cancer is the most common carcinoma in females
and the second leading cause of cancer death in women
[1]. The sentinel lymph node (SLN) status, an accurate
predictor of axillary lymph node status, has been shown
to be one of the most important prognostic factors in
breast cancer [2]., Sentinel lymph node biopsy (SLNB) is
a safe and reliable technique that is well accepted as a
standard procedure in breast cancer surgery with clinic-
ally negative lymph nodes [3].
Currently, different tracer materials have been reported
in SLNB of breast cancer, such as blue dye, radioisotope,
carbon nanoparticles, or a combination [4, 5]. However,
there is no consensus regarding the optimal tracer mate-
rials for SLNB [6]. The detection rate of blue dye is lower
than that of radioisotope despite its cost effectiveness and
safety [4]. The application of radioisotope in SLNB is
hampered by the risk of radiation exposure and poor
quality of lymph vessel mapping [7, 8]. The use of
carbon nanoparticles is limited by the high cost.
Therefore, the development of new tracer materials
for SLNB is still needed.
Fluorescein sodium (FS) is a fluorescent dye that is
widely used in ophthalmic surgery and malignant brain
tumor surgery [9, 10]. Ten percent FS, a widely available
substance, is conventionally safe without any clearly
associated adverse effects. Furthermore, FS was reported
to be an effective tracer material for SLN mapping in
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colorectal tumors [11]. However, to our knowledge, the
use of FS in SLNB of breast cancer has not been re-
ported previously. In this study, we aimed to compare
the usefulness of 10 % FS and 1 % isosulfan blue (com-
monly used blue dye) to investigate the feasibility of
using 10 % FS in SLNB of breast cancer.
Methods
Animal experiments
Thirty female New Zealand White rabbits weighing be-
tween 2.0 and 2.5 kg were randomly divided into the FS
group and isosulfan blue group (15 rabbits each group).
Solutions of 10 % FS (Santa Cruz Biotechnology,
Dallas, TX, USA) and 1 % isosulfan blue (US Surgical
Corp, North Haven, CT, USA) were prepared using ster-
ile water for injection as the solvent. Rabbits were anes-
thetized with pentobarbital intravenously (15 mg/ml,
2 ml/kg, pentobarbital sodium; Sigma, St, Louis, MO,
USA). After anesthesia, rabbits were positioned supine
and the planned injection sites were clipped. The skin
flaps were elevated from the second mammary glands
and extended to fossa axillaris bilaterally. Careful blunt
dissection was performed to avoid the injury of blood
vessels and lymphatic vessels. Intradermal injection of
0.3 ml 10 % FS or 1 % isosulfan blue was made at the bi-
lateral sites of the second mammary gland of rabbits in
FS group or isosulfan blue group, respectively.
The operating room lights were adjusted to the dim
mode, and a hand-held 485-nm wavelength blue light
source (Model: LTS-RN9070; Ling Liang Vision, Shanghai,
China) was used as exciting light for FS. Goggles with a
blue light filter were equipped to search for the yellow-
green FS-detected SLNs (Fig. 1). The FS-detected SLNs
were defined as the first one to two fluorescent lymph
nodes in the dark background. The FS-detected second
lymph nodes were defined as the fluorescent lymph nodes
receiving drainage from the FS-detected SLNs and con-
nected with the fluorescent lymphatic vessels. On the
other hand, the isosulfan blue-detected lymph nodes were
observed under the operating room lights in the regular
mode. The isosulfan blue-detected SLNs were defined as
the first one to two blue-stained lymph nodes visible in
the fossa axillaris area. The isosulfan blue-detected second
lymph nodes were blue-stained lymph nodes that received
drainage from the isosulfan blue-detected SLNs. The two
tracers were compared for the average dyeing time of the
sentinel and second lymph nodes, average fading time of
the sentinel and second lymph nodes, detection rates, dis-
tances between the detected SLNs and second pair of
mammary areolas, and distances between the second
lymph nodes and second pair of mammary areolas, as well
as the number of detected SLNs and second lymph nodes.
After the observation of all of the data, animals were
sacrificed with pentobarbital intravenously (325 mg/ml,
10 ml).
Statistical analysis
The numerical data were presented as the means ±
standard deviation (SD), and p values were calculated by
Student’s t test. Fisher’s exact test was used to compare
the detection rates of SLNs between the two groups. All
of the statistical analyses were carried out using STATA
11 (StataCorp LP, College Station, TX, USA). Differences




All rabbits in the FS group and isosulfan blue group
were kept in the same cleaning cages and were fed with
the same rabbit feed (corn 80 %, hay 10 %, bran 5 %,
bone meal 3 %, salt 2 %, no autofluorescence ingredient
was included). No significant differences were observed
between the FS group and isosulfan blue group regard-
ing weight, the distances between the detected sentinel
lymph nodes and second pair of mammary areolas, or
the distances between the second lymph nodes and sec-
ond pair of mammary areolas (Table 1).
Fig. 1 LTS-RN9070 blue light source system and goggle with blue
light filter
Table 1 General aspects of animals in two groups
Variable FS group IS group p value
Body weight (kg) 2.54 ± 0.17 2.56 ± 0.15 0.57
Distance from SNP to SLN (cm) 11.39 ± 3.14 12.34 ± 1.72 0.23
Distance from SNP to 2nd LN (cm) 15.09 ± 2.86 15.22 ± 1.64 0.89
FS fluorescein sodium, IS isosulfan blue, SNP the second pair of nipples, SLN
sentinel lymph node, 2nd the second lymph node
*p < 0.05
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Afferent lymphatic vessels stained by FS and isosulfan
blue
The afferent lymphatic vessels stained by FS were easily
visualized under florescent light even when they were
covered by tissues (Figs. 2 and 3). However, the lymph-
atic vessels stained with isosulfan blue were faint and
difficult to observe under incandescent or fluorescent
light. The detection rate of afferent lymphatic vessels
using FS was higher than that using isosulfan blue (100
vs 80 %, respectively) (Table 2).
Comparison of FS and isosulfan blue in lymph node
dissection
A mean of 1.36 SLNs per side and a mean of 0.88 of the
second lymph nodes per side were identified in the FS
group. By contrast, the average number of SLNs and sec-
ond lymph nodes per side identified in the isosulfan blue
group was 1.38 and 0.79, respectively. No significant dif-
ferences were found between the two groups (Table 2).
There were no significant differences between the FS
group and isosulfan blue group in the average dyeing
time of the SLNs (142 vs 206 s) and second lymph nodes
(502 vs 483 s, respectively). Furthermore, no significant
differences were observed between the FS group and iso-
sulfan blue group in the fading time of SLNs (4327 vs
3482 s, respectively). However, the fading time of the
second lymph nodes was much longer in the FS group
than in the isosulfan blue group.
The detection rates of SLNs in the FS group were
each 100 %. By contrast, the detection rates of SLNs
in the isosulfan blue group (80 %) were significantly
lower than those in the FS group (p = 0.024). To fur-
ther investigate the superiority of FS in SLN detec-
tion, we performed intradermal injection of 0.3 ml of
10 % FS into the second mammary gland of rabbits
in which isosulfan blue was failed to detect the SLNs.
All of the SLNs that could not be detected in the iso-
sulfan blue group were successfully identified by the
supplementary injection of FS.
Side effects
No side effects were observed in either the FS group or
isosulfan blue group during the process of tracer injec-
tion and lymph node dissection.
Discussion
Isosulfan blue is the first dye to be approved by the USA
Food and Drug Administration for the localization of
the lymphatic system [12]. Although various tracer ma-
terials for SLNB have emerged in the past two decades,
isosulfan blue is still accepted as one of the most effect-
ive tracers in SLNB because of the simplicity of its use
and availability [11]. Despite the wide use of isosulfan
blue in SLNB of breast cancer, isosulfan blue has
been reported to cause erroneous pulse oximetry
readings [13]. Furthermore, the relatively high cost of
isosulfan blue has limited its popularization in devel-
oping countries.
FS was reported as an alternative tracer with some
clear advantages in sentinel node mapping in colorectal
tumors. In this study, 1 % isosulfan blue was used as a
control tracer to compare the usefulness of FS with that
of isosulfan blue and to evaluate the feasibility of using
10 % FS in SLNB of breast cancer.
Isosulfan blue is a reliable tracer material in lymph-
atic vessel identification during SLNB of breast cancer
[14, 15]. However, the detection rate of afferent
lymphatic vessels by isosulfan blue is only 80 % in
our study. By contrast, all of the afferent lymphatic
vessels were identified in the FS group. On the other
hand, it may take a long time for surgeons to learn
the blue dye method [16]. Our results have shown
that the fluorescence in FS-stained lymphatic vessels and
lymph nodes could easily penetrate the fur and tissues of
rabbits and could be visualized percutaneously. Thus, FS-
based SLNB is much easier to perform and requires a
shorter learning curve than isosulfan blue.
In our study, the detection rate of SLNs was 80 %
for isosulfan blue-guided SLNB, a finding that is con-
sistent with that in other studies showing a detection
rate ranging from 75 to 90 % with isosulfan blue dye
[17, 18]. By contrast, the identification rate of SLNs
in the FS group was 100 %.
Skip metastases are not very common, and the inci-
dence has been reported to be 15 % for breast cancer
[19]. However, the presence of skip metastasis and
non-sentinel lymph node metastasis did affect the
success of SLNB in breast cancer. Therefore, it is
essential to evaluate the effectiveness of tracers in
identifying second lymph nodes that are considered
Fig. 2 Percutaneously observable FS signal in a lymphatic vessel.
The second mammary glands are stained by FS (arrow head), and
the afferent lymphatic vessel is stained by FS (arrow)
Ren et al. World Journal of Surgical Oncology  (2016) 14:280 Page 3 of 5
potential metastatic non-sentinel lymph nodes. In our
study, there was no statistically significant difference
in the average dyeing time and number of second
lymph nodes in the FS group compared with those in
the isosulfan blue group. Nevertheless, the fading
time of second lymph nodes was much longer in the
FS group than in the isosulfan blue group, potentially
providing surgeons with additional time to identify
the metastatic non-sentinel lymph nodes.
As a fluorescent dye, indocyanine green (ICG) has
been regarded as a novel method in SLNB in breast
cancer. The detection rate of using ICG was reported
to be 80 %, which is slightly lower than that of FS [20].
Furthermore, the use of ICG is associated with high
cost equipment [21]. Recently, a new non-radioactive
method was developed, using superparamagnetic iron
oxide (SPIO) nanoparticles as tracer and manual mag-
netometer as detector. This new method was reported
to be non-inferiority compared to the combination of
radioisotope and blue dye. However, the application of
SPIO is limited by the high cost and the requirement of
special plastic surgical material, while the usage of FS
as tracer for SLNB is more economical (5 ml FS: 20 US
dollar, goggle: 30 US dollar/pair, blue light source: 400
US dollar).
Conclusions
In summary, our study is the first report to compare the
use of 10 % FS and 1 % isosulfan blue in SLN mapping
of breast cancer. We found that it is feasible and safe to
use FS in SLNB of breast cancer. Moreover, as a poten-
tial tracer, FS is superior to isosulfan blue regarding
certain aspects of SLNB of breast cancer. However, our
data are based on animal models; further studies are still
required to evaluate the safety and feasibility of using FS
in SLNB of breast cancer in patients.
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Fig. 3 Lymphatic vessel and lymph node stained by FS
Table 2 Comparative analysis of various parameters between
two groups
Variable FS group IS group p value
Detection rate of ALV 100 % (30/30) 80 % (24/30) 0.024*
Number of the 2nd LN 1.36 ± 0.62 1.13 ± 0.65 0.92
Dyeing time of the SLN (s) 142 ± 69 206 ± 219 0.28
Dyeing time of the 2nd LN (s) 502 ± 417 483 ± 305 0.91
Fading time of the SLN (s) 4327 ± 2359 3482 ± 1680 0.3445
Fading time of the 2nd LN (s) 3918 ± 2196 1332 ± 443 0.0077*
Detection rate of the SLN 100 % (30/30) 80 % (24/30) 0.024*
FS fluorescein sodium, IS isosulfan blue, ALV afferent lymphatic vessels, SLN
sentinel lymph node, 2nd the second lymph node
*p < 0.05
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